PortfoliosLab logoPortfoliosLab logo
VRNA vs. QS
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

VRNA vs. QS - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Verona Pharma plc (VRNA) and QuantumScape Corporation (QS). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period


VRNA

1D
1M
YTD
6M
1Y
3Y*
5Y*
10Y*

QS

1D
-1.94%
1M
-18.13%
YTD
-31.96%
6M
-39.92%
1Y
57.91%
3Y*
-1.86%
5Y*
-23.97%
10Y*
*Multi-year figures are annualized to reflect compound growth (CAGR)

VRNA vs. QS - Yearly Performance Comparison


2026 (YTD)202520242023202220212020
VRNA
Verona Pharma plc
0.00%130.21%133.60%-23.92%288.84%-4.00%-15.15%
QS
QuantumScape Corporation
-31.96%100.77%-25.32%22.57%-74.45%-73.72%757.36%

Correlation

The correlation between VRNA and QS is 0.01, meaning there is essentially no relationship between their price movements. Each responds to its own set of market drivers, making them strong candidates for combining in a diversified portfolio.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.01

Correlation (3Y)
Calculated over the trailing 3-year period

0.16

Correlation (5Y)
Calculated over the trailing 5-year period

0.19

Correlation (All Time)
Calculated using the full available price history since Aug 17, 2020

0.18

The correlation between VRNA and QS shifts across timeframes, from 0.01 (1 year) to 0.19 (5 years), reflecting how their relationship changes across market environments.

Fundamentals

Market Cap

VRNA:

$9.72B

QS:

$4.33B

EPS

VRNA:

-$0.69

QS:

-$0.72

PB Ratio

VRNA:

34.92

QS:

3.90

Total Revenue (TTM)

VRNA:

$167.65M

QS:

$0.00

Gross Profit (TTM)

VRNA:

$159.52M

QS:

-$49.03M

EBITDA (TTM)

VRNA:

-$40.86M

QS:

-$378.92M

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

VRNA vs. QS — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

VRNA

Risk / return metrics aren't available yet — we need at least 12 months of trading data to calculate them.


QS
QS Risk / Return Rank: 6363
Overall Rank
QS Sharpe Ratio Rank: 6262
Sharpe Ratio Rank
QS Sortino Ratio Rank: 7070
Sortino Ratio Rank
QS Omega Ratio Rank: 6767
Omega Ratio Rank
QS Calmar Ratio Rank: 6161
Calmar Ratio Rank
QS Martin Ratio Rank: 5757
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

VRNA vs. QS - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Verona Pharma plc (VRNA) and QuantumScape Corporation (QS). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.


VRNAQSDifference
Sharpe ratioReturn per unit of total volatility

Sortino ratioReturn per unit of downside risk

Omega ratioGain probability vs. loss probability

1.19

Calmar ratioReturn relative to maximum drawdown

0.86

Martin ratioReturn relative to average drawdown

1.33

VRNA vs. QS - Sharpe Ratio Comparison


Loading charts...

Drawdowns

VRNA vs. QS - Drawdown Comparison


Loading charts...

Drawdown Indicators


VRNAQSDifference

Max Drawdown

Largest peak-to-trough decline

-97.36%

Max Drawdown (1Y)

Largest decline over 1 year

-67.68%

Max Drawdown (3Y)

Largest decline over 3 years

-73.93%

Max Drawdown (5Y)

Largest decline over 5 years

-91.45%

Current Drawdown

Current decline from peak

-94.62%

Average Drawdown

Average peak-to-trough decline

-85.52%

Ulcer Index

Depth and duration of drawdowns from previous peaks

43.64%

Volatility

VRNA vs. QS - Volatility Comparison


Loading charts...

Volatility by Period


VRNAQSDifference

Volatility (1M)

Calculated over the trailing 1-month period

25.60%

Volatility (6M)

Calculated over the trailing 6-month period

48.92%

Volatility (1Y)

Calculated over the trailing 1-year period

103.22%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

85.76%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

105.87%

Dividends

VRNA vs. QS - Dividend Comparison

Neither VRNA nor QS has paid dividends to shareholders.


Tickers have no history of dividend payments

Financials

VRNA vs. QS - Financials Comparison

This section allows you to compare key financial metrics between Verona Pharma plc and QuantumScape Corporation. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.0020.00M40.00M60.00M80.00M20222023202420252026
75.14M
0
(VRNA) Total Revenue
(QS) Total Revenue
Values in USD except per share items

Frequently Asked Questions


VRNA and QS have a correlation of 0.01, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Portfolio Optimizer

Find the right allocation for VRNA and QS

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer